title: Proteasome inhibitors suppress expression of NPM and ARF proteins.
abstract: Proteasome inhibitors stabilize numerous proteins by inhibiting their degradation. Previously we have demonstrated that proteasome inhibitors thiostrepton, MG132 and bortezomib paradoxically inhibit transcriptional activity and mRNA/protein expression of FOXM1. Here we demonstrate that, in addition to FOXM1, the same proteasome inhibitors also decrease mRNA and protein expression of NPM and ARF genes. These data suggest that proteasome inhibitors may suppress gene expression by stabilizing their transcriptional inhibitors.
authors.affiliation: Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: Bulbul
authors.initials: B
authors.lastname: Pandit
authors.forename: Andrei L
authors.initials: AL
authors.lastname: Gartel
mesh_terms: D020727:ADP-Ribosylation Factors / Q000235:genetics*; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D000072278:Forkhead Box Protein M1; D051858:Forkhead Transcription Factors / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects*; D006367:HeLa Cells; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D013883:Thiostrepton / Q000494:pharmacology
chemical_list: D001897:Boronic Acids; D015853:Cysteine Proteinase Inhibitors; C107585:FOXM1 protein, human; D000072278:Forkhead Box Protein M1; D051858:Forkhead Transcription Factors; D007976:Leupeptins; D009687:Nuclear Proteins; D061988:Proteasome Inhibitors; D011719:Pyrazines; D012333:RNA, Messenger; D000090243:Nucleophosmin; D000069286:Bortezomib; D020727:ADP-Ribosylation Factors; D013883:Thiostrepton; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde
references.citation: Oncogene. 2007 Aug 2;26(35):5154-62
references.pmid: 17334400
references.citation: Mol Cell Biol. 2005 Feb;25(4):1258-71
references.pmid: 15684379
references.citation: Cancer Invest. 2004;22(2):304-11
references.pmid: 15199612
references.citation: Oncotarget. 2011 Mar;2(3):209-21
references.pmid: 21444945
references.citation: Annu Rev Biochem. 1999;68:1015-68
references.pmid: 10872471
references.citation: Expert Opin Investig Drugs. 2010 Feb;19(2):235-42
references.pmid: 20074015
references.citation: Cell Cycle. 2010 Nov 1;9(21):4282-5
references.pmid: 20980825
references.citation: Nat Rev Cancer. 2004 May;4(5):349-60
references.pmid: 15122206
references.citation: Cell. 1996 Mar 22;84(6):813-5
references.pmid: 8601303
references.citation: Oncotarget. 2010 May;1(1):6-8
references.pmid: 21293050
references.citation: PLoS One. 2009;4(5):e5592
references.pmid: 19440351
references.citation: Oncotarget. 2011 May;2(5):418-21
references.pmid: 21789791
references.citation: PLoS One. 2011 Feb 18;6(2):e17110
references.pmid: 21365012
references.citation: Cell Cycle. 2010 Feb 1;9(3):523-30
references.pmid: 20107325
references.citation: Cell Cycle. 2009 Jun 15;8(12):1966-7
references.pmid: 19411834
references.citation: PLoS One. 2009 Aug 12;4(8):e6593
references.pmid: 19672316